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First, I would like to briefly describe the Barcelona Centre for In­
ternational Health Research (CRESIB). CRESIB’s mission is to 
find solutions to current and future global health challenges. It 
was established in 2006 by a group of first­rate academic and 
biomedical research institutions (the Hospital Clínic de Barcelo­
na, the University of Barcelona, and the August Pi i Sunyer Bio­
medical Research Institute) and by the Government of Catalo­
nia. More recently, in 2009, with the support of the ”La Caixa” 
Foundation, CRESIB became the research arm of the Barcelo­
na Institute for Global Health (ISGlobal). This institution is the 
fruit of an innovative alliance between academic, government, 
and philanthropic organizations. It seeks to provide a hub of ex­
cellence in research and healthcare that will help close the gaps 
in health disparities between and within different regions of the 
world. It includes a think tank, aimed at the management of 
knowledge and designed to influence policy; a training centre, 
aimed at the transmission of knowledge, and a technical assis­
tance centre, aimed at the application of knowledge. In 2013, 
ISGlobal and CRESIB signed an agreement with the Centre for 
Research in Environmental Epidemiology (CREAL) to become a 
world­leading alliance in the field of global health. 
CRESIB carries out multidisciplinary and translational re­
search in molecular biology, physiopathology, immunology, 
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Resum. El 2001, el Banc Mundial va assenyalar que el proble­
ma més gran que la humanitat afrontaria en el segle XXI seria la 
pobresa. Avui dia sabem que 1.200 milions de persones, aproxi­
madament una cinquena part de la població mundial, viuen amb 
menys d’un dòlar al dia i que les malalties transmissibles conti­
nuen representant la meitat de les morts i gairebé dos terços 
dels anys de vida ajustats per discapacitat (AVADs) entre el 20 % 
més pobre de la població mundial. Des d’una perspectiva de 
salut global, es tracta d’una bretxa d’equitat en salut inaccepta­
ble. Si els medicaments i les mesures preventives existents fos­
sin més accessibles, ara mateix podrien salvar milions de vides. 
Alhora, la investigació de nous medicaments i vacunes, i llur 
desenvolupament clínic posterior, són essencials per a obtenir 
munició eficaç contra les malalties que mantenen les persones 
en situació de pobresa. A la vista d’aquests reptes per la salut 
global, cal que els potencials beneficis de la medicina personalit­
zada compleixin avaluacions basades en la investigació, incloent 
la utilitat clínica, el baix cost i la factibilitat tècnica, en el marc de 
sistemes de salut prou sòlids, i amb personal degudament ca­
pacitat. Cal potenciar els partenariats amb països de baixos i 
mitjans ingressos, amb el suport del Programa Marc Horitzó 
2020 de Recerca de la UE.
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Summary. In 2001, the World Bank stated that the biggest 
problem facing humanity in the 21st century would be pover­
ty. Today, we know that 1200 million people, about a fifth of 
the world’s population, lives on less than a dollar a day and 
that communicable diseases continue to account for half of 
the deaths and almost two thirds of the disability­adjusted life 
years (DALYs) among the poorest 20 % of the world’s popu­
lation. From a global health perspective, this is an unaccepta­
ble health equity gap. If the existing medicines and preventa­
tive measures were made more widely available, they could 
already save millions of lives. At the same time, research into 
new drugs, vaccines, etc., and their subsequent clinical de­
velopment are crucial to obtaining effective ammunition 
against diseases that keep people in poverty. In the view of 
such global health challenges, the potential benefits of per­
sonalised medicine need to meet research­based evalua­
tions, including clinical utility, low­cost and technical feasibili­
ty, within responsive healthcare systems with adequately 
trained personnel. Partnerships with low and middle­income 
countries, with the support of the incoming EU Horizon 2020 
Research Framework  Programme, need to be promoted.
Keywords: personalised medicine ∙ global health ∙ poverty­
related diseases ∙ health equity
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clinical characterization, and epidemiology, as well as in the 
clinical development of treatment and prevention tools, such 
as vaccines. Gradually, we have pursued downstream ap­
proaches with the monitoring and evaluation of public health. 
Broadly stated, our goal is to improve global health through re­
search and training, with our main areas of work focused on 
malaria, imported diseases, HIV/AIDS and STDs, viral and bac­
terial infections, and other emerging disease­related activities. 
We use a cross­sectional approach, including public health, 
social sciences and medical anthropology, maternal, child and 
reproductive health, and host­pathogen interactions.
Finally, one of the main features of our efforts is that we col­
laborate with more than 100 institutions from 40 countries 
across the five continents, including stable partnerships with 
high quality research capacities in low­income countries such 
as Mozambique, Morocco, and Bolivia. As such, ISGlobal is a 
centre committed to translating research into action.
The global health vision
One way to define Global health is ‘public health without bor­
ders.’ More specifically, this means:
•   Better health for all, taking into account current disparities 
and inequalities, with particular attention to the needs of 
the most vulnerable; in other words, health as a human 
right.
•   A  global  perspective  on  both  scientific  inquiry  and  the 
translation of knowledge into practice.
•   A  scientific  approach  to  health  promotion  and  disease 
prevention, examining broad determinants of health, in­
cluding but not limited to, medical care.
•   An interdisciplinary approach and collaborative team work 
that includes population problems analysis.
•   Multilevel  systems-based  interventions:  society, govern­
ance, corporate responsibility, environmental, behaviour­
al, and biological risk factors.
•   Comprehensive frameworks for financing and structuring 
health policies and services that support community­
based and clinical prevention integrated with healthcare 
delivery. [2]
Within this approach, I would like to emphasise the issue of 
equity, because if we talk about a global health point of view, 
the major challenge facing humanity is the unacceptable health 
equity gap. Indeed, today, in the 21st century, our life expec­
tancy is still largely determined by where we are born. 
Figure 1 shows the distribution of income as well as life ex­
pectancy in different countries over time. At the beginning of 
the last century, in the 1900s, life expectancy varied worldwide, 
from about 25 to approximately 50 years, but with relatively lit­
tle difference either in life expectancy among countries or in 
terms of per capita income. In the 1950s, the spread became 
quite substantial. For some countries, those shown in blue, 
and specifically many African countries but also some East 
Asian countries, there was very little change during those 50 
years. In the 1990s, the spread continued to increase, with 
some of these countries starting to move up, not so much in 
terms of income but rather in life expectancy. Finally, there is 
currently good and bad news. The good news is that in African 
and East Asian countries, as in most countries, life expectancy 
has steadily improved; but the bad news is that, overall, dis­
crepancies among countries have increased, ranging from less 
than 50 years for in some low­income countries to more than 
80 years in high­income countries.
For example, in the mid­20th century, a very large part of the 
world had infant mortality rates that were quite high, between 
15 and 20 ‰ (per thousand). Fifty years later, at century’s end, 
the picture had for the most part changed completely, with a 
reduction of more than 100 % (Fig. 2). So this is the good news. 
Fig. 1. Correlation between life expectancy (years) and income per 
person (GDP per capita, PPPs inflation­adjusted) in 1900, 1950, 1990 
and 2011. Source: Gapminder [www.gapminder.org]
Fig. 2. Child mortality by country, 1960 and 1990. Child mortality has 
fallen sharply in the past 30 years, with particularly rapid declines in 
parts of Asia and Latin America. Source: World Bank [5].
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But if we look at the data on a regional basis, we see that al­
though infant mortality has improved in all regions, there are 
large differences among them. For children under the age of 
five years, mortality has decreased overall, but the worst rates 
are still those of the African continent.
The 20th century Smallpox was eradicated, while we are not 
far from the eradication of polio and measles. There has been a 
decrease in overall mortality and life expectancy at birth has in­
creased substantially, by 25 years on average. Mean individual 
wealth has also increased at an unprecedented rate, accom­
panied by a very strong technological revolution. These 
achievements are proof that with effective strategies and the 
proper involvement of governments, industries, scientists, etc., 
we can achieve success on a scale never seen before in the 
history of humankind. 
But, is all the news genuinely good? Not really. Today, we 
know that 1200 million people, about a fifth of the world’s pop­
ulation, lives on less than a dollar a day and that communicable 
diseases continue to account for half of the deaths and almost 
two thirds of the disability­adjusted life years (DALYs) among 
the poorest 20 % of the world’s population. And for children 
around the globe, infectious diseases, such as diarrhoea, 
pneumonia, malaria, HIV/AIDS and measles, account for a 
substantial share of these figures (Table 1). Again, Africa and 
Southeast Asia suffer the highest share of this burden, largely 
because of the impact of infectious diseases. 
In 2001, the World Bank stated that the biggest problem 
facing humanity in the 21st century would be poverty. Disease 
generates poverty, and poverty generates disease. Nonethe­
less, the positive view of the situation, is that the percentage of 
people living on less than 1.25 US$ a day—that is, in extreme 
poverty—has decreased by half (from 43 % to 22.4 %). In fact, 
while in 1990, 1.9 billion people lived in extreme poverty, by 
2008 the number had decreased to 1.29 billion. But it is impor­
tant to remember that this improvement has been very une­
qually distributed throughout large parts of the world. Both in 
Africa and in some Asian countries, a majority of the population 
still lives in extreme poverty, which means an especially high 
risk of many diseases, and not just infectious diseases (Fig. 3). 
Former US Secretary of State General George C. Marshall, 
responsible for the Marshall Plan, the American program of aid 
to Europe after WWII, said over half a century ago, in 1948, that, 
“Little imagination is required to visualise the great increase 
in the production of foods and raw materials, the stimulus to 
world trade and above all the improvement in living condi­
tions, with consequent social and cultural advances that 
would result from the conquest of tropical diseases.” [4]
As shown in Fig. 4, which lists the leading causes of death 
by income group, in low income countries, infections of the 
lower respiratory tract are the first cause of death, whereas is­
chemic heart disease is the most frequent cause worldwide 
and in high income countries. Nonetheless, cerebrovascular 
diseases (stroke ischemic heart disease) already rank among 
the ten major causes of death at all ages in low income coun­
tries, curiously mimicking the situation in the world as a whole 
and in some high­income countries. The same is true for some 
infectious diseases. But, in general, diseases of poverty con­
tinue to account for a large share of deaths. Furthermore, most 
countries are experiencing an epidemiological and behavioural 
transition, i.e., in addition to the burden already posed by mal­
nutrition and communicative diseases, there is the growing 
burden of non­communicable, so­called chronic diseases. 
At the same time, the major disease determinants or risk 
factors are increasingly similar in low income as in high income 
countries. Many of these risk factors are largely amenable to 
environmental interventions. Thus, we already have the knowl­
edge that can help us to confront globally many of these risks. 
It is also important to keep in mind, from this global perspec­
Fig. 3. Percentage of the population living on less than 1.25 US$ a day 
at 2005 international prices. Source: World Bank [6].
Table 1. Distribution of child deaths for selected causes by selected WHO region, 2004*
Africa South­East Asia Rest of the World
All causes 45 % 30 % 25 %
Diarrhoeal diseases 45 % 35 % 20 %
Pneumonia 50 % 25 % 25 %
Malaria 90 % 5 % 5 %
HIV/AIDS 90 % 5 % 5 %
Measles 45 % 45 % 10 %
*Percentages rounded to the nearest 5 %. Source: World Health Organisation [7].
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tive, that there is a lack of equity in the provision of health care 
services. One of the classical examples is maternal mortality, a 
good indicator of the access to primary or obstetrical care or 
the lack thereof with more than ten­fold differences among 
countries. Again, the issues of poverty and the inequitable dis­
tribution of different diseases are highly relevant.
The role of research in global health
The role of research in global health is a longstanding one. Fig­
ure 5 is a very interesting British cartoon from the 1920s that 
depicts malaria draining the life out of tropically based indus­
tries, including tea, coffee, vegetable oil, and copper; that is, 
several of the main sources of revenue for the British Empire. 
The work of Sir Ronald Ross, who received the 1902 Nobel 
Prize for his work on malaria, and the Ross Institute and Hospi­
tal for Tropical diseases were already seen as means to avoid 
or at least to minimise the devastating impact of malaria—and 
by extension of other infectious diseases—on business and the 
economy. The concerns depicted in the cartoon are still very 
familiar ones today, i.e., high costs and low efficiency, and im­
plicitly emphasise the important role of research in global health 
to contribute to a productive economy.
If they were made more widely available, the existing med­
icines and preventative measures for the above­mentioned 
diseases could already save millions of lives, although none 
of them can completely eliminate HIV/AIDS, TB, or malaria. 
At the same time, research into new drugs, vaccines, etc., 
and their subsequent clinical development are crucial to ob­
taining effective ammunition against diseases that keep peo­
ple in poverty. Yet, of the 1233 new drugs that reached the 
market between 1975 and 1997, only 13 were for tropical 
diseases primarily affecting the poorest populations. This is 
known as the “10/90 gap” and, while not a real quantitative 
measure, it has become a symbol of the continuing mis­
match between global health needs and the investments to 
meet them. Indeed, investment studies by the Global Forum 
for Health Research (www.globalforumhealth.org) continue 
to demonstrate that “health research applied to the needs of 
low­ and middle­income countries (LMICs) remains grossly 
under­resourced in many areas”. 
Potential for personalised medicine in global 
health
So how can personalised medicine contribute to global health? 
On the one hand, overall, we humans throughout the world are 
probably much more genetically similar than different. While this 
is a very broad statement, it is meant to point out that many of 
the findings obtained by research in wealthy countries can be 
generalised to the whole world. But to what extent do these 
one­size­fits­all strategies meet our needs? We are at the early 
development stages of both personalised medicine and the dif­
ferent ‘­omics.’ Thus, we need evidence­based medicine and 
research into the comparative effectiveness of newly developed 
therapies if we are to make informed decisions in this area. 
So what are the real benefits of personalised medicine and 
what are the prospects for LMICs? The answers to these ques­
tions are closely linked to the need for research aimed at meet­
ing those challenges through, for example:
•   Better or targeted interventions, vaccines, or drugs; here, 
vaccinomics is an area of potential interest.
•   Diagnostic, screening, or predictive tests.
•   The need for firmly established research and care capaci­
ties (laboratory genomics, biobanks, epidemiologic co­
hort studies, clinical studies, randomised control trials, 
gene­based technologies, etc.)
•   Collaborative  research  involving  investigators  from  low 
and middle income countries and high income countries, 
including multidisciplinary and public­private partner­
ships.
•   Need for training and education of the workforce.
•   Ethical and legal frameworks.
•   Equity of access. [3]
Accordingly, is personalised medicine, from a global health 
standpoint, a priority? Most of the targets for public health in­
Fig. 4. Top ten causes of death in (A) low income countries vs. (B) high income countries, 2011. Source: World Health Organisation.
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terventions, as described, are on the environmental side, with 
different strategies and stakeholders, including economic, so­
cial, and political ones. There is also a predominance of risk 
factors that are amenable to environmental modification. At the 
same time, we cannot forget that these strategies are likely to 
be effective for most of the previously discussed risk factors, 
such that the aim is to promote a more equitable provision of 
health services. Many of LMICs have very limited resources for 
health services and their distribution tends to be inequitable, 
which raises issues of global justice and human rights. It has 
been pointed out that: 
 “A major challenge is to generate an evidence base that can 
demonstrate that a genomics approach is at least as safe, 
effective and cost effective in these settings as other, more 
traditional approaches, such as modifying environmental or 
social determinants.” [1]
In this context, are there precedents of potential interest? 
Here we need to consider:
1.  Areas with clearly established evidence of clinical utility, 
for example, the prenatal or neonatal detection of certain 
inherited diseases.
2.  Areas with currently available low­cost solutions, for ex­
ample, the more systematic use of family history informa­
tion.
3.  Areas with the scope for targeted innovative technical 
solutions, especially regarding prevalent infectious dis­
eases.
In general, there is a need for a public health genomics ap­
proach that is applicable to all countries but at the same time 
relevant on a smaller scale. Here, efforts should include select­
ing evidence­based applications, maximizing heath benefits 
and reducing inequities, reducing harm and unnecessary 
healthcare expenditures (premature or inappropriate use), eval­
uating public health interventions, and fostering capacity build­
ing in research and clinical care.
When we talk about personalised medicine and global 
health challenges we are also talking about the ability to en­
large the scope of research to include partnerships among 
low, middle­, and high­income countries. Only through such 
partnerships will we succeed in introducing whatever benefits 
or effective innovations come of them in order to improve 
global health. As an example, for over twenty years, the Clínic 
Foundation, Barcelona, and the Spanish Agency of Interna­
tional Cooperation have partnered with the Health Research 
Center in Manhiça, Mozambique. The initial focus was malar­
ia, but the partnership has expanded to other areas and is 
now part of a research network of African centres. 
Global health R&D on the near horizon?
As a final point, let me underline that efforts have been made 
to include the topics of global­poverty­related and neglected 
diseases in the next EU Research Framework Programme, 
Horizon 2020, and in the relevant discussions of the Europe­
an Parliament and the European Commission. Market forces 
alone will not lead to the development of sufficient, affordable, 
and appropriate new technologies and goods for these dis­
eases. Public support and public financing are required when 
public goods are under­supplied by the market, as is the case 
for drugs used in the treatment of malaria, TB, and HIV/AIDS, 
several of which were effectively introduced over the last dec­
ade in many developing countries. Horizon 2020 presents an 
opportunity for the European Union to step in as a leader in 
addressing market failure and in stimulating innovation. 
It is crucial to raise awareness and to mobilise members 
of the European Parliament and EU policy­makers in sup­
porting stronger EU investment and commitment—both po­
litical and financial—in the fight against poverty­related and 
neglected diseases. This also means raising the issue of the 
cost­effectiveness of investing in R&D for global health and 
the potential of innovations in this field to for strengthen Eu­
rope’s research leadership.
Why? Basically because we can also strengthen the EU 
economy through support for an essential but challenged area 
of European innovation, by providing a competitive advantage 
for European industry and research. Improving the health not 
just of Europeans but globally will have positive effects on 
health systems, employment, and global health security. It can 
also contribute to sustaining the credibility of the EU in its com­
mitments, made through a wide range of EU policies including 
those on health, economic growth, social inclusion, and devel­
opment. Global health efforts can facilitate progress in other 
areas, such as science diplomacy, knowledge sharing, and 
common solutions to problems. 
I end this contribution with a quote appropriate to this global 
approach to science, from India’s first Prime Minister, Jawaha­
rlal Nehru (1889–1964), considered the architect of this devel­
oping country’s modern nation­state,
“Who indeed could afford to ignore science today? At every 
turn we have to seek its aid... The future belongs to science 
and to those who make friends with science.”
Fig. 5. Appeal in 1926 for subscriptions to funds for research on 
tropical diseases (From ‘Tropical Life’, London).
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